Jim Simons Bio N Tech Se Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$102.58 - $129.66 $6.62 Million - $8.37 Million	-64,572 Reduced 12.67%	445,019 $48 Million
Q1 2023 May 12, 2023	BUY	$122.57 - $153.67 $21.8 Million - $27.4 Million	178,107 Added 53.73%	509,591 $63.5 Million
Q4 2022 Feb 13, 2023	BUY	$118.43 - $186.05 $39.3 Million - $61.7 Million	331,484 New	331,484 $49.8 Million
Q2 2022 Aug 12, 2022	SELL	$123.25 - $186.24 $1.45 Million - $2.2 Million	-11,800 Reduced 4.71%	238,619 $35.6 Million
Q1 2022 May 13, 2022	BUY	$126.25 - $231.85 $31.6 Million - $58.1 Million	250,419 New	250,419 $42.7 Million
Q3 2021 Nov 12, 2021	SELL	$205.93 - $447.23 $67.7 Million - $147 Million	-328,614 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$113.32 - $241.49 $37.2 Million - $79.4 Million	328,614 New	328,614 $73.6 Million

358

38.4M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $29.6B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.